Table 3.
Criteria | Scores | Coef | Total (score*coef) | ||||
---|---|---|---|---|---|---|---|
Diagnostic tools | 2 | 1 | 0 | −1 | −2 | 4.17 | /100 |
1. Availabilitya | |||||||
2. Prevention and control - Differentiation of infected from vaccinated (DIVA) | |||||||
3. Strategic reserve | |||||||
4. Capacity of production | |||||||
5. Market potential | |||||||
6. Affordable | |||||||
7. Quality/stability durability | |||||||
8. Sensitivity | |||||||
9. Specificity | |||||||
10. Reproducibility | |||||||
11. Simplicity/ease of use | |||||||
12. Speed | |||||||
Vaccination tools | 2 | 1 | 0 | −1 | −2 | 4.55 | /100 |
1. Commercial availabilitya | |||||||
2. Monitoring for infection in a vaccinated population | |||||||
3. Strategic reserve | |||||||
4. Capacity of production | |||||||
5. Market potential | |||||||
6. Affordable | |||||||
7. Quality/stability | |||||||
8. Safety of vaccines | |||||||
9. Efficacy | |||||||
10. Immunity | |||||||
11. Convenience of use | |||||||
Pharmaceutical tools | 2 | 1 | 0 | −1 | −2 | 4.55 | /100 |
1. Availabilitya | |||||||
2. Prevention and control | |||||||
3. Strategic reserve | |||||||
4. Capacity of production | |||||||
5. Market potential | |||||||
6. Cost | |||||||
7. Quality | |||||||
8. Safety animal | |||||||
9. Safety consumer/user concerns | |||||||
10. Safety environment | |||||||
11. Resistance | |||||||
Total Score: |
aA maximum score of 20 was given to the whole criterion when there isn’t any product available (not even under development)